RB1 and diffuse intrinsic pontine glioma: The second study is a phase I clinical trial (NCT03355794) assessing the safety, feasibility, and pharmacokinetic profile of ribociclib and everolimus as maintenance therapy following radiotherapy in pediatric patients with newly diagnosed DIPG, DIPG with biopsy positive for the presence of the retinoblastoma (RB) protein, and HGG [184].